Research Overview
Across the provided abstracts, research on chanca piedra (commonly marketed for kidney stone prevention/management) has been studied primarily in the context of over-the-counter (OTC) supplement use rather than as a rigorously tested therapeutic agent. The most developed areas include: (1) market and utilization analyses of OTC “kidney stone” products and their common ingredients; (2) evaluation of the quality and reliability of online information driving consumer interest; and (3) compositional testing relevant to stone risk (e.g., oxalate content per dose). Related work on OTC alkalinizing supplements more broadly emphasizes cost, dosing, and regulatory considerations compared with prescription potassium citrate, but does not establish clinical efficacy for specific herbal ingredients such as chanca piedra.
The strongest evidence in these abstracts supports caution rather than efficacy. Specifically, the ingredient-focused analysis found that clinical evidence supporting stone prevention for common OTC ingredients (including chanca piedra) is limited or absent in the available literature, while public interest and online engagement are high and the reliability of online articles is poor by DISCERN scoring. In addition, direct chemical analysis identified measurable oxalate content in chanca piedra (8.2 mg per dose), which is relevant because oxalate is a key constituent in many kidney stones; however, the abstracts do not establish whether this amount meaningfully affects urinary oxalate or stone outcomes in vivo.
Key gaps requiring further research include well-designed human clinical studies testing chanca piedra’s efficacy and safety for stone prevention and/or facilitation of stone passage, with clinically meaningful endpoints (recurrence, stone burden, time to passage) and mechanistic urinary parameters (citrate, pH, calcium, oxalate, supersaturation). Additional needs include standardized product characterization (dose, active constituents, batch-to-batch consistency), assessment of adulteration/mislabeling risk in online-sold herbal products (highlighted by DNA barcoding concerns for herbal medicinal products generally), and evaluation of whether the oxalate content or other constituents of chanca piedra alter stone risk in different patient subgroups.
1. What conditions has Chanca Piedra been studied for?
Kidney stones / nephrolithiasis / urolithiasis (stone prevention and “stone management”): In the provided abstracts, chanca piedra appears specifically in the context of over-the-counter (OTC) supplements marketed to treat kidney stones and evaluated for their ingredients and composition.
Urinary stone disease prevention strategies (as part of OTC alkalizing supplement discussions): One abstract reviews OTC alkalizing agents used for stone prevention; it does not single out chanca piedra as an alkalizing agent, but it frames the broader OTC supplement landscape for stone prevention.
Product authenticity/adulteration risk for herbal medicinal products sold online: One abstract addresses DNA barcoding to authenticate single-ingredient herbal products sold online (relevant to chanca piedra as an online-sold herbal product category), though the excerpt does not name chanca piedra specifically.
2. Does it work in treating those conditions? Summarize the evidence.
Clinical efficacy for kidney stone prevention/treatment is not established in these abstracts. The Amazon-best-seller ingredient review concludes that evidence for stone prevention for common supplement ingredients was “limited or lacking altogether” based on their literature review; chanca piedra is one of the commonly found ingredients they analyzed.
No direct demonstration of benefit is provided in the abstracts. The abstracts presented do not report randomized trials or clinical outcomes (e.g., reduced stone recurrence, improved urinary citrate, reduced stone size) specifically attributable to chanca piedra.
Overall conclusion from the OTC supplement literature in these abstracts: additional investigations are needed to determine composition and clinical efficacy of OTC ingredients used for stone management, including chanca piedra.
3. What health benefits does it have?
Proposed/marketed benefit (not confirmed here): It is commonly included in OTC supplements marketed to treat kidney stones (nephrolithiasis), indicating a claimed antilithogenic role.
Evidence-based benefits from these abstracts: The provided abstracts do not establish specific health benefits for chanca piedra (e.g., prevention of stone recurrence or improved urinary chemistry). Instead, they emphasize that evidence is limited or lacking.
Practical “benefit” noted indirectly: OTC supplements are widely available online and attract high public interest; however, this reflects popularity rather than proven efficacy.
4. Does it have any downsides or side effects?
Oxalate content (potential downside for stone formers): The ingredient analysis found chanca piedra contained 8.2 mg oxalate per dose. For individuals advised to limit oxalate intake (e.g., calcium oxalate stone formers), this could be a concern depending on total daily oxalate exposure and dosing frequency.
Quality/control concerns for online herbal products: The herbal medicinal product authentication abstract highlights that, due to limited FDA regulation, manufacturers may substitute or add other herbs not listed on the label. While not specific to chanca piedra in the excerpt, this is a relevant risk category for single-ingredient online-sold herbal products.
Misinformation risk: Online articles about supplement ingredients for kidney stones showed poor reliability (DISCERN-based assessment). This can lead to inappropriate self-treatment or delayed evidence-based care.
Side effects: The provided abstracts do not report clinical adverse event rates or specific side effects attributable to chanca piedra.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
The provided abstracts do not discuss pharmacogenomics, genetic variants, or genotype-specific benefits/risks for chanca piedra. Therefore:
No evidence from these abstracts that chanca piedra is beneficial or harmful for specific genetic variations.
Key limitation: Without genotype-stratified clinical studies or mechanistic data tied to specific pathways/enzymes/transporters, pharmacogenomic conclusions cannot be made from the cited material.
References
-
Alkalinizing Agents: A Review of Prescription, Over-the-Counter, and Medical Food Supplements
Karen L Stern, Noah Canvasser, Michael Borofsky, Vanessa M Gleason, Guido Kamphuis (2020) -
DNA Barcoding of Online Herbal Supplements: Crowd-sourcing Pharmacovigilance in High School.
Jeanmaire Molina, Chhoti Sherpa, Joyee Ng, Tenzin Sonam, Nicole Stuhr (2018) - Open life sciences -
Evaluation of the Online Information Landscape and Oxalate Content of Purportedly Antilithogenic Ingredients
Karan N Thaker, Ava Mousavi, Tamara Keenum, Sapna Thaker, Parris Diaz (2025)
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!